Aemetis, Inc. (NASDAQ:AMTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Aemetis, Inc. (NASDAQ:AMTX - Get Free Report) have received an average recommendation of "Moderate Buy" from the four analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.44.

A number of equities analysts recently issued reports on the company. UBS Group lowered their price target on Aemetis from $8.25 to $7.75 and set a "buy" rating on the stock in a report on Monday, August 19th. StockNews.com raised Aemetis to a "sell" rating in a report on Wednesday, July 31st. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of Aemetis in a report on Friday, August 2nd. Truist Financial reiterated a "hold" rating and issued a $3.50 price objective (down from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. Finally, Ascendiant Capital Markets cut their price objective on shares of Aemetis from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Tuesday.

View Our Latest Report on AMTX

Aemetis Trading Down 2.0 %

Aemetis stock opened at $2.41 on Tuesday. The stock has a market cap of $113.75 million, a P/E ratio of -2.10 and a beta of 1.31. The company has a fifty day simple moving average of $2.99 and a 200-day simple moving average of $3.56. Aemetis has a 12-month low of $2.10 and a 12-month high of $7.03.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The specialty chemicals company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The company had revenue of $66.56 million for the quarter, compared to analysts' expectations of $75.37 million. During the same quarter in the prior year, the company earned ($0.68) EPS. As a group, sell-side analysts forecast that Aemetis will post -2.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aemetis

A number of institutional investors and hedge funds have recently bought and sold shares of AMTX. SG Americas Securities LLC purchased a new stake in Aemetis during the 1st quarter worth about $60,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis during the first quarter worth about $84,000. Bank of New York Mellon Corp acquired a new position in shares of Aemetis in the second quarter valued at approximately $306,000. Rhumbline Advisers lifted its stake in shares of Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company's stock valued at $157,000 after buying an additional 50,528 shares during the period. Finally, Hutchinson Capital Management CA acquired a new stake in Aemetis during the second quarter worth approximately $70,000. Hedge funds and other institutional investors own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.

Featured Stories

• Five stocks we like better than Aemetis
• The How and Why of Investing in Gold Stocks
• Don’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings
• Procter & Gamble NYSE: PG Pulls Back After Shaky Guidance
• Why Lululemon's Setback Could Be Your Next Big Win
• What is a Stock Market Index and How Do You Use Them?
• 3 Best Dividend Stocks to Buy as Interest Rates Fall

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad)

Should you invest $1,000 in Aemetis right now?

Before you consider Aemetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.

While Aemetis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here